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Abstract
Introduction: Despite years of research, there are no disease-modifying drugs for Alzheimer’s disease (AD), a fatal,
age-related neurodegenerative disorder. Screening for potential therapeutics in rodent models of AD has generally
relied on testing compounds before pathology is present, thereby modeling disease prevention rather than disease
modification. Furthermore, this approach to screening does not reflect the clinical presentation of AD patients
which could explain the failure to translate compounds identified as beneficial in animal models to disease
modifying compounds in clinical trials. Clearly a better approach to pre-clinical drug screening for AD is required.
Methods: To more accurately reflect the clinical setting, we used an alternative screening strategy involving the
treatment of AD mice at a stage in the disease when pathology is already advanced. Aged (20-month-old)
transgenic AD mice (APP/swePS1ΔE9) were fed an exceptionally potent, orally active, memory enhancing and
neurotrophic molecule called J147. Cognitive behavioral assays, histology, ELISA and Western blotting were used to
assay the effect of J147 on memory, amyloid metabolism and neuroprotective pathways. J147 was also
investigated in a scopolamine-induced model of memory impairment in C57Bl/6J mice and compared to
donepezil. Details on the pharmacology and safety of J147 are also included.
Results: Data presented here demonstrate that J147 has the ability to rescue cognitive deficits when administered
at a late stage in the disease. The ability of J147 to improve memory in aged AD mice is correlated with its
induction of the neurotrophic factors NGF (nerve growth factor) and BDNF (brain derived neurotrophic factor) as
well as several BDNF-responsive proteins which are important for learning and memory. The comparison between
J147 and donepezil in the scopolamine model showed that while both compounds were comparable at rescuing
short term memory, J147 was superior at rescuing spatial memory and a combination of the two worked best for
contextual and cued memory.
Conclusion: J147 is an exciting new compound that is extremely potent, safe in animal studies and orally active.
J147 is a potential AD therapeutic due to its ability to provide immediate cognition benefits, and it also has the
potential to halt and perhaps reverse disease progression in symptomatic animals as demonstrated in these
studies.
Introduction
Alzheimer’s disease (AD) is characterized pathologically
by the presence of both extracellular neuritic plaques
and intracellular neurofibrillary tangles [1]. Clinically,
AD results in a progressive loss of cognitive ability as
well as daily function activities [2,3]. At the time when
most patients are diagnosed with AD, the pathology is
usually at an advanced stage. Currently approved thera-
pies are only symptomatic in nature, providing modest
improvements in memory without altering the progres-
sion of the disease pathology [4,5]. Thus, effective dis-
ease modifying treatments that also provide cognition
benefits are urgently required.
Age is the greatest risk factor for developing AD, leading
us to develop a drug discovery procedure that is based
upon old-age-associated pathologies without requiring
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pre-selected molecular targets [6,7]. A series of six cell
culture assays was designed to mimic multiple old-age-
associated pathways of central nervous system (CNS)
nerve cell damage, and drug candidates were required to
show efficacy in all of these assays before being moved for-
ward into animals. As potential lead drug candidates, we
generated a large number of derivatives of the curry spice
curcumin, which is effective in AD transgenic mice [8,9].
Based upon activity in multiple CNS toxicity assays, we
identified an exceptionally potent, orally active, neuro-
trophic molecule called J147 that facilitates memory in
normal rodents, and prevents the loss of synaptic proteins
and cognitive decline when administered to three-month-
old APP/swePS1ΔE9 mice for seven months [7]. The neu-
rotrophic and memory-enhancing activities of J147 are
associated with an increase in the level of brain derived
neurotrophic factor (BDNF) along with the expression of
BDNF-responsive proteins, the enhancement of long term
potentiation (LTP), synaptic protein preservation, the
reduction of markers for oxidative stress and inflamma-
tion, the reduction of amyloid plaques, and lower levels of
soluble Ab1-42 and Ab1-40. These combined neuroprotec-
tive and memory enhancing effects of a single molecule
suggest that J147 has significant potential for the treat-
ment of AD.
To more closely mimic the clinical setting, we have
now examined the effect of J147 in transgenic mice at a
stage when pathology is significantly advanced and
asked if the drug could rescue some of the symptoms.
This study used the well characterized APPswe/PS1ΔE9
mouse model that exhibits a subset of behavioral and
pathological features of AD, including age-dependent
accumulation of beta-amyloid (Ab) as well as learning
and memory deficits [10]. This model was previously
used to demonstrate the neuroprotective and memory
enhancing effects of J147 when administered before
pathology is present [7]. In comparison, the AD mice in
this study were allowed to age to 20 months before
being fed J147 for 3 months. We demonstrate that J147
has the ability to rescue the severe cognitive deficits pre-
sent in aged, transgenic AD mice. In addition, J147
enhances the expression of BDNF and nerve growth fac-
tor (NGF) and additional proteins associated with their
signaling pathways. Therefore, the reversal of cognitive
deficits as well as some other aspects of AD pathology




High glucose Dulbecco’s modified Eagle’s medium
(DMEM) and fetal calf serum (FCS) were obtained from
Invitrogen (Carlsbad, CA, USA). C57BL/6J mice were
ordered from Jackson Labs (Sacramento, CA, USA)
Stock 000664. The transgenic mouse line APPswe/
PS1ΔE9 85 was a generous gift of Dr. J.L. Jankowsky.
The primary antibodies were used at a dilution of
1:1,000 unless otherwise stated and their sources and
molecular weights were as follows: Cell Signaling Tech-
nology (Danvers, MA, USA): b-actin, monoclonal HRP
conjugate, 45 kDa; CREB, monoclonal, 43 kDa. Santa
Cruz Biotechnology (Santa Cruz, CA, USA): Egr-3, C-24
polyclonal, 42 kDa; BDNF, polyclonal, 16 kDa. Millipore
(Temecula, CA, USA): Anti-BACE C-terminus, clone
61-3E7, 60 to 75 kDa. Novus Biologicals (Littleton, CO,
USA): Homer-1, polyclonal, 47 kDa. Sigma (St Louis,
MO, USA): Anti-Amyloid Precursor Protein, C-terminal,
polyclonal, 95 to 100 kDa; Anti-Nerve Growth Factor
2.5S, polyclonal homodimer, 26 kDa. Covance (Prince-
ton, NJ, USA): 6E10 monoclonal antibody.
All other materials were from Sigma (St Louis, MO,
USA) unless otherwise stated.
Methods
Animal studies
All animal studies were carried out in strict accordance
with the recommendations in the Guide for the Care and
Use of Laboratory Animals of the National Institutes of
Health. The protocol was approved by the Committee on
the Ethics of Animal Experiments of the Salk Institute for
Biological Studies.
Old huAPPswe/PS1ΔE9 transgenic mice
Animals
The APPswe/PS1ΔE9 transgenic mice (line 85) have
been previously characterized [10,11]. The line 85 mice
carry two transgenes, the mouse/human chimeric APP/
Swe, linked to Swedish FAD and human PS1ΔE9. At 20
months of age both male and female transgenic mice
were fed a high fat diet (Harlan Tekland, Madison, WI,
USA) with and without J147 (200 ppm, 10 mg/kg/day).
Treatment continued for three months and was followed
by behavior testing and sacrifice of mice for tissue har-
vesting. Mouse body weights and food consumption
were measured weekly, and there were no significant
differences between the groups. (Data not shown).
C57BL/6J mice-scopolamine study
Animals
A total of 60 male mice aged eight weeks were housed 4
per cage and were divided into five groups with 12 mice
per group. Treatments were administered in the food
(TestDiet® 5015, Richmond, IN, USA) for a period of
two weeks before commencement of behavioral testing.
Groups included J147 at 200 ppm (10 mg/kg/day),
donepezil at 20 ppm (1 mg/kg/day), a combination of
J147 at 200 ppm and donepezil at 20 ppm, and two
groups on the control food without any treatments.
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Following two weeks of treatment, memory impairment
was induced by intraperitoneal (i.p.) injection of scopo-
lamine (1 mg/kg) 30 minutes prior to each of the fol-
lowing behavioral tests: Y-maze, probe trial of the water
maze and contextual and cued fear conditioning. Mice
were allowed to rest for two days between each behavior
test. All mice received scopolamine except for one of
the control groups, which received saline as a control.
Mice were sacrificed 24 hours after the last behavioral
test for tissue harvesting.
Behavior assays
Two-day water maze
Spatial memory was determined using the two-day water
maze in 23-month-old huAPPswe/PS1 transgenic mice
fed J147 at 200 ppm in food for the previous three
months. The protocol was adapted from a publication
by Gulinello and colleagues [12]. Water temperature
remained at 27°C throughout the experiment. The goal
platform was positioned 45 cm from the outside wall in
the north-west quadrant of the maze for all groups and
all trials. Day 1 of the two-day water maze procedure
involved training the mice to find the platform using
cues located around the pool within a 180 s time frame.
This training involved a series of visible platform trials
where mice were tracked using the Noldus EthoVision
software (Noldus Information Technology, Inc., Lees-
burg, VA, USA). There were four visible platform trials
(V1 to V4) where the last visible platform trial of a
mouse was considered its post-habituation baseline. If
the mice failed to find the platform after 180 s, they
were placed on the platform by the experimenter. All
mice remained on the platform for 15 s before being
placed in a heated incubator (30°C) between trials. On
Day 2, 24 hours following the last visible platform trial,
mice were tested in a series of three hidden platform
trials (T1 to T3). Again each trial lasted for 180 s. The
time it took each mouse to find the hidden platform
was measured as escape latency. For the scopolamine
experiment, normal mice were given an i.p. injection of
saline or 1 mg/kg scopolamine 30 minutes before the
first hidden platform trial on Day 2. All trials were
recorded using the EthoVision Software and statistics
were computed using GraphPad Instat software (Graph-
Pad Software, San Diego, CA, USA).
Elevated plus maze
The elevated plus maze analyzes the anxiety response of
mice [13]. This test relies upon the tendency of mice to
have a fear of heights and to navigate towards dark
enclosed spaces and remain there [14]. Our maze is
made of gray plastic and consists of four arms (two
open without walls and two enclosed by 15.25 cm high
walls) 30 cm long and 5 cm wide in the shape of a plus
sign. The elevated plus maze is placed close to the
center of the room, and has similar levels of illumina-
tion on both open and closed arms. A video-tracking
system (Noldus EthoVision) is used to automatically col-
lect behavioral data. The software is installed on a PC
computer with a digital video camera mounted overhead
on the ceiling, which automatically detects and records
when mice enter the open or closed arms of the maze
and the time spent in each. Mice are habituated to the
room 24 hours before testing. Mice are also habituated
to the maze for two minutes before testing by placing
them in the center of the maze and blocking entry to
the arms. Mice were then tested in the maze for a five-
minute period while the software tracked and recorded
the behavior of the mice. The anxiety of mice was mea-
sured by comparing the time spent in the open arms to
time spent in the closed arms. Statistics were computed
using GraphPad Instat software.
Fear conditioning assay
Fear conditioning to either a cue or a context represents a
form of associative learning. The read-out that is mea-
sured in contextual and cued fear conditioning is a freez-
ing response that occurs following the pairing of an
unconditioned stimulus (US), such as a foot shock, with a
conditioned stimulus (CS), such as a particular context or
cue (tone) [15-17]. The mouse will freeze if it remembers
and associates that environment with the aversive stimu-
lus. The hippocampus and the amygdala are required for
fear memory where the hippocampus is involved in the
formation and retrieval of context fear associations and
the amygdala is involved in conditioning and recall of
associations to contextual and discrete cues [18,19]. This
assay used fear conditioning chambers from Med Associ-
ates Inc. with Video Freeze Software (Med Associates Inc,
St. Albans, VT, USA). On Day 1, mice were trained by
allowing them to explore the chamber for 120 sec, mice
were then presented with a 30-sec tone (2 kHz with 85 dB
intensity) immediately followed by a 2-sec foot shock (0.7
mA). The tone-shock pairing was repeated following a
30-sec interval and the mice were again allowed to explore
for 120 sec before removing them from the chamber. On
Day 2, contextual memory, which requires a functioning
hippocampus, was tested by placing the mice in the cham-
bers and allowing them to explore for the same length of
time as the previous day but without the tone and the
shock. On Day 3, cued or emotional memory was tested,
which relies on both hippocampus and amygdala. For this,
the chamber environment was altered by using plastic
boards to alter the shape of the chamber and using similar
plastic boards over the grid floor to alter the environment
further. Vanilla essence was used to alter the smell of the
environment. Testing involved placing the mice in the
chambers and carrying out the same paradigm as Day 1
without the foot shock. The camera measures the amount
of time the mice freeze and the software allows analysis of
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this freezing at any time-point of interest. On Day 2, the
time spent freezing is measured over the entire time in the
chamber. A mouse that remembers the chamber context
and associates it with the foot shock will spend more time
freezing and this response is hippocampal dependent. The
percentage of time spent freezing by each mouse is aver-
aged per group and then groups can be compared and
P-values calculated to determine statistical significance. On
Day 3, the percentage of time spent freezing during the two
tones is averaged per group, and then groups can be com-
pared and P-values calculated to determine statistical signif-
icance. This result relates to the recall of associations to the
tone and is dependent on the amygdala and the hippocam-
pus. For the scopolamine experiment, normal mice were
administered an i.p. injection of saline or 1 mg/kg scopola-
mine 30 minutes before testing on Day 2 and Day 3.
Y-Maze
Spontaneous alternation, the tendency to alternate free
choices in a Y-maze (three arms), is a model for study-
ing short term working memory in mice [20,21]. Mice
were injected with 1 mg/kg of scopolamine or saline 30
minutes prior to testing. Then each mouse was placed
in the center of the Y and arm entries were recorded by
video camera and the order of entries were recorded for
the first 15 entries. Spontaneous alternations are defined
as consecutive triplets of different arm choices.
Tissue preparation and immunoblotting
Hippocampal and entorhinal cortex tissue samples were
homogenized in 10 volumes of RIPA lysis buffer (50 mM
Tris, pH 7.5, 150 mM NaCl, 0.1% sodium dodecyl sulfate
and 0.5% deoxycholate, and 1% NP40) containing a cocktail
of protease and phosphatase inhibitors (20 mg/ml each of
pepstatin A, aprotinin, phosphoramidon, and leupeptin;
0.5 mM 4-(2-aminoethyl) benzenesulfonyl fluoride hydro-
chloride; 1 mM EGTA; 5 mM fenvalerate; and 5 mM
cantharidin). Samples were sonicated (2 × 10 s) and centri-
fuged at 100,000 × g for 60 minutes at 4°C. Protein concen-
trations in the cell extracts were determined using the BCA
protein assay (Pierce supplied by Thermo Fisher Scientific,
Rockford, IL, USA). Equal amounts of protein were solubi-
lized in 2.5x SDS-sample buffer, separated on 12% SDS-
polyacrylamide gels, transferred to Immobulin P and
immunoblotted with the antibodies indicated in the Mate-
rials section. For Western blots, protein levels were nor-
malized to actin levels. An unpaired t test was performed
to compare between two groups at a single time point.
When comparing multiple groups, one-way ANOVA fol-
lowed by a Tukey’s post hoc test was used. All statistical
analysis was conducted using GraphPad Instat software.
Immunohistochemistry
Brains were fixed with 4% paraformaldehyde in 100 mM
sodium tetraborate, pH 9.5, for 3 h, cryoprotected with
20% sucrose-potassium-PBS (KPBS), and sectioned into
coronal (30 μm) sections using a sliding microtome
(Leica Microsystems Inc, Buffalo Grove, IL, USA).
Sections were submerged in 0.3% H2O2 for 10 minutes
to eliminate endogenous peroxidase activity and treated
with 1% borate to eliminate free paraformaldehyde.
Sections were incubated with primary antibody in 0.3%
Triton X-100 in KPBS plus 2% filtered serum or BSA
overnight at 4°C, and with primary antibodies (1:1,000)
in 0.3% Triton X-100 for 1 hr at room temperature.
After incubation with secondary antibody and ABC
reagent (Vector Laboratories Inc, Burlingame, CA,
USA), sections were developed using metal-enhanced
DAB solution. Sections were mounted to slides, dried,
dehydrolyzed, treated with xylene, and covered using
permount (Fisher Scientific, Pittsburgh, Pennsylvania,
USA). Images were captured by a Zeiss digital camera
connected to a Zeiss VivaTome microscope (Carl Zeiss
Microscopy, LLC, Thornwood, NY, USA), and image
analysis on sections was performed using Axiovision
software (Carl Zeiss Microscopy, LLC, Thornwood, NY,
USA).
Quantification of amyloid plaque burden was based on
the image captured by immunohistochemical staining
with antibody 6E10. Sections of each mouse cortex and
hippocampus were imaged together and the areas and
densities of the plaques in the hippocampus only were
measured by the Image J software (NIH). The total
counts of Ab plaques in sections per six mouse brains
of each group were determined in an unbiased fashion.
Ab ELISA
Ab 1 to 40 and 1 to 42 levels in hippocampal lysate were
analyzed using the Ab1-40 and Ab1-42 ELISA kits from
Invitrogen (# KHB3481 and # KHB3442, respectively).
All kit reagents were brought to room temperature
before use. Standards were prepared according to the
manufacturer’s guidelines and samples were diluted as
follows; RIPA fractions were diluted 1:10 for both Ab1-40
and Ab1-42; and RIPA insoluble fractions were diluted
1:2,000 for Ab1-40 and 1:5,000 for Ab1-42. A total of 50 μl
of Ab peptide standards and samples were added in
duplicate to 96-well plates pre-coated with mAb to the
NH2 terminus region of Ab. Plates were incubated at 4°C
overnight and then 50 μl of Hu Ab40 or Ab42 detection
antibody was added to each well except the chromogen
blanks. Plates were incubated at room temperature with
gentle shaking for three hours and then washed four
times with the provided wash buffer. At this time, 100 μl
of anti rabbit IgG HRP working solution was added to
each well except the chromogen blanks for 30 minutes at
room temperature. Wells were then washed as before
four times and incubated with 100 μl of stabilized chro-
mogen for 25 minutes at room temperature in the dark.
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Stop solution was then added at 100 μl to each well fol-
lowed by reading the absorbance of each well at 450 nm.
Curve fitting software was used to generate the standard
curve where a four-parameter algorithm provided the
best standard curve fit. The concentrations of the sam-
ples were calculated from the standard curve and multi-
plied by the dilution factor.
Cell culture with growth conditioned medium
The HT22 cell line was used to make growth condi-
tioned medium. HT22 is a nerve cell line derived from
mouse brain and is widely used to study nerve cell phy-
siology [22,23]. To make HT22 growth conditioned
medium, cells were grown in DMEM with 10% fetal calf
serum. Then, semiconfluent cultures were washed three
times with serum-free DMEM and cultured overnight in
a reduced volume of DMEM in the presence or absence
of 100 nM J147. The following day, the growth condi-
tioned medium was collected and centrifuged at 10,000
× g to remove detached cells. To determine the effect of
the conditioned medium on NGF-induced neurite out-
growth, PC12 cells were dissociated and plated on poly-
ornithine-coated tissue culture dishes in the following
conditions: 1) HT22 conditioned medium, 2) J147 trea-
ted HT22 conditioned medium, 3) DMEM alone plus
J147, 4) DMEM plus NGF at 50 nanograms per ml, 5)
J147 treated HT22 conditioned medium pre-incubated
for one hour with 10 μg/ml anti-NGF and N2 supple-
ment (Invitrogen). N2 supplement, which contains
transferrin, was used in the presence of antibody to
minimize the possibility that antibody protein non-spe-
cifically modified cell-substrate from adhesion and
therefore neurite outgrowth. Phase contrast photographs
were taken 24 hrs later.
GeneChip
HT22 cells
HT22 cells were plated in DMEM plus 10% FCS. The
next day, the cells were treated with 10 μM J147 for
1 hr before RNA isolation.
RNA isolation
RNA was isolated with the use of RNeasy Mini kit (Qia-
gen, #74104; Valencia, CA, USA) according to the man-
ufacturer’s instructions. Total RNA was quantified using
the ND-1000 Nanodrop and assessed for quality using
the ratios: A260/280 (range: 1.9 to 2.1) and A260/230
(range: 2.0 to 2.2, if <2.0, contamination), in addition to
the Bioanalyzer (Agilent Technologies, Cedar Creek, TX,
USA) if further quality assessment was required.
RNA isolation and microarray hybridization experiments
After RNA isolation for each sample, double stranded
cDNA was synthesized from 500 ng total RNA and bio-
tin-labeled using the GeneChip 3’ IVT Express Kit
(Affymetrix, Santa Clara, CA, USA, #901228-A) per the
manufacturer’s instructions and protocol. RNA was pur-
ified, quantified, fragmented randomly to an average size
of 50 to 200 bases and hybridized to GeneChip® Mouse
Genome 430 2.0 Arrays (Affymetrix,) consisting of over
45,000 probe sets representing more than 34,000 named
mouse genes. The hybridization and processing of the
GeneChips were conducted by Salk Institute’s Func-
tional Genomics Core Facility using the following sys-
tems from Affymetrix (Santa Clara, CA, USA):
GeneChip® Hybridization Oven 640, GeneChip® Flui-
dics Station 450 to the wash and stain operation of Affy-
metrix GeneChip® arrays, and the GeneChip® Scanner
3000 7G.
GeneChip quantification and normalization
Affymetrix Expression Console Software (version 1.0) was
used to perform quality assessment of the microarray
scan/experiments. Array data were normalized via scaling
to adjust the average intensity of each array to be similar.
GeneChips were analyzed by the GeneChip Operating
Software (Affymetrix) with the default settings except that
the target signal was set to 200 for GeneChip quality con-
trol. Raw data were analyzed through the gcRMA-algo-
rithm using the Affymetrix package in R software for
statistical computing and graphics [24]. The median
microarray intensity for all microarrays was normalized to
100, and probe sets with median intensities >100 were
scored. Fold changes were calculated in Microsoft Excel
Microsoft, Redmond, Washington, USA). Genes of interest
and genes with the highest fold-changes were validated
using Real-Time Quantitative PCR. The data discussed in
this publication have been deposited in NCBI’s Gene
Expression Omnibus [25] and are accessible through GEO
Series accession number GSE45534 [26].
Commercial screening for molecular targets and “off
target” effects
All screening was done at 10 μM J147 by various contract
research organizations (CROs), including MDS Pharma
Services (King of Prussia, PA, USA), Ricerca, now Panlabs
(Concord, OH, USA), Ambit (La Jolla, CA, USA), Caliper
(Hopkinton, MA, USA) and NovaScreen Biosciences
(Hanover, MD, USA) by standard protocols described in
their catalogs. The only two assays that yielded greater
than 60% inhibition at 10 μM J147 were then re-assayed
to determine EC50 values: the dopamine transporter (EC50
= 0.649 μM) and monoamine oxidase B (EC50 = 1.88 μM)
assays both carried out by MDS Pharma Services.
Synthesis of J147 and donepezil
Materials
Compounds J147 and donepezil were synthesized in our
laboratory at the Salk Institute. All starting materials, che-
micals and reagents were obtained from Sigma Aldrich,
(Milwaukee, WI, USA), and were used as received.
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Solvents used for synthesis and chromatographic analysis
were HPLC or ACS reagent grade and were purchased
from Fisher Scientific Co (Pittsburg, PA, USA). Thin layer
chromatography (TLC) used EMD silica gel F-254 plates
(thickness of 0.25 mm). Flash chromatography used EMD
silica gel 60, 230 to 400 mesh and were purchased from
EMD Chemicals (San Diego, CA, USA).
Analytical methods
1H NMR recorded at 500, on a Varian VNMRS-500
spectrometer at the Salk Institute (La Jolla, CA, USA)
using the indicated solvents. Chemical shift (δ) is given
in parts per million (ppm) relative to tetramethylsilane
(TMS) as an internal standard. Coupling constants (J)
are expressed in hertz (Hz), and conventional abbrevia-
tions used for signal shape are as follows: s = singlet;
d = doublet; t = triplet; m = multiplet; dd = doublet of
doublets; brs = broad singlet. Liquid chromatography
mass spectrometry (LCMS) was carried out using a Shi-
madzu LC-20AD spectrometer at The Scripps Research
Institute (La Jolla, CA, USA), and electrospray ionization
(ESI) mass analysis with a Thermo Scientific LTQ Orbi-
trap-XL spectrometer at the Salk Institute. Melting
points were determined with a Thomas-Hoover capillary
melting point apparatus at the Salk Institute, and are
uncorrected. All final compounds were characterized by
LCMS and 1H NMR and gave satisfactory results in
agreement with the proposed structure. J147 and done-
pezil have purity of 98% and 99%, respectively, which
was determined by analysis on a C18 reverse phase
HPLC column (Phenomenex Luna (50 mm × 4.60 mm,
3 μm)) at The Scripps Research Institute, using 10 to
90% CH3CN/H2O containing a 0.02% AcOH with a flow
rate of 1 mL/min (5-minute gradient) and monitoring
by a UV detector operating at 254 nm.
Chemical synthesis of compounds
The synthesis of J147 has been carried out using simple
chemistry as described in our previous paper by conden-
sation of 3-methoxybenzaldehyde and (2, 4-dimethyl-
phenyl) hydrazine hydrochloride in EtOH at room
temperature, followed by acetylation using trifluoroace-
tic anhydride and triethylamine in CH2Cl2 gave J147
(Scheme 1). Donepezil has been synthesized with 99%
purity according to the literature procedure published in




A mixture of 3-methoxybenzaldehyde (50 g, 367.64
mmol) and (2, 4-dimethylphenyl) hydrazine hydrochlor-
ide (63.23 g, 367.64 mmol) in EtOH (50 mL) was stirred
at room temperature for 1 h, the obtained solid was fil-
tered off, washed with ethanol and dried under vacuum
to afford hydrazone hydrochloride 1 (95.94 g) in 90%
yield as a light brown solid. This unstable hydrazone (50
g, 172.41 mmol) was dissolved in CH2Cl2 (50 ml), Et3N
(57.56 mL, 413.79 mmol) followed by (CF3CO)2O
(28.77 mL, 206.89 mmol), was added at 0°C and the
mixture was stirred at room temperature for 1 h. Reac-
tion mixture was diluted with aq. sat. NaHCO3 solution
(500 mL), extracted with CH2Cl2 (2 × 500 mL), dried
(Na2SO4) and evaporated, resulting solid was recrysta-
lized from ethanol to give J147 (49.11 g, 81%) as a white
solid: mp 70 to 72°C; LCMS purity 98%; 1H NMR
(CDCl3, 500 MHz) δ ppm 2.10 (s, 3H), 2.42 (s, 3H),
3.82 (s, 3H), 6.98 (dd, J = 8.5, 2.0 Hz, 1H), 7.07 (d, J =
7.5 Hz, 1H), 7.14 (d, J = 8.0 Hz, 1H), 7.28 (m, 3H). MS
(ESI): m/z calcd for C18H17F3N2O2 ((M + H) +)
351.1314; found 351.1366 ((M + H) +).
Results
The early intervention strategy is most frequently used
for drug testing in AD because drug candidates assayed
in AD transgenic mice at the stage when pathology is
already present are generally less effective [27-30]. How-
ever, treating aged, transgenic AD mice in an AD rever-
sal type investigation is a valuable experiment that
should provide important pre-clinical information about
the ability of compounds to rescue cognitive deficits in
AD patients. We used 20-month-old line 85 APPswe/
PS1ΔE9 transgenic AD mice (huAPP/PS1) to examine
the effect of J147 on the physiological, behavioral and
pathological aspects of the disease when administered
late in the course of the disease. Pathological hallmarks
of AD, including plaques and loss of synaptic markers,
are readily apparent at nine months of age in huAPP/
PS1 mice along with clear deficits in spatial memory
when compared to wild type controls [7,10,11,31]. Wild
type controls were not included in this study because
deficits in huAPP/PS1 mice compared to wild type con-
trols have already been extensively characterized and
documented in the literature [7,10,11,31].
J147 rescues cognitive deficits in aged Alzheimer’s
disease mice
Both male and female huAPP/PS1 mice were aged to 20
months. At this time, the mice were randomly assigned
to one of two groups: 11 mice were fed normal food
and 13 mice were fed the same diet but also containing
200 ppm J147. This concentration of J147 converts to
approximately 10 mg/kg/day per mouse and was chosen
based upon the potency of J147 in our recently pub-
lished study [7]. Following three months of treatment,
all mice were analyzed for spatial memory performance
by the two-day water maze (Figure 1A), disinhibition
phenotype by the elevated plus maze (Figure 1B), and
contextual and cued memory by a fear conditioning
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assay (Figure 1C and 1D, respectively). There were no
significant differences between the sexes within each
group.
The two-day water maze analyzes spatial navigational
memory [12], which is impaired in huAPP/PS1 mice
when compared to wild type littermates [10,32]. This
water maze differs slightly from the traditional Morris
Water Maze which involves a five- to seven-day training
period to analyze learning and a final probe day to ana-
lyze memory [33]. Briefly, a platform which is visible
Figure 1 J147 rescues cognitive deficits in aged Alzheimer’s disease mice. huAPP/PS1 mice were aged to 20 months old. The mice were
then put on the control food diet or 200 ppm J147 food diet (10 mg/kg/day). Following three months of treatment, all mice were analyzed for
spatial memory by the two-day water maze, disinhibition phenotype by the elevated plus maze and hippocampal dependent memory by fear
conditioning. (A) The two-day water maze analyzes spatial navigational memory. Visible V4 refers to visible platform trial 4 (Day 1), which is the
last visible platform trial before testing and, therefore, represents the baseline. During testing on Day 2, the time it takes each mouse to find the
hidden platform during trial 1 (hidden T1) is measured as escape latency. AD mice control (white boxes), took considerably longer to find the
hidden platform than AD mice fed J147 (black boxes), suggesting that J147 improved the navigational memory of mice. (B) The elevated plus
maze analyzes the anxiety response of mice by comparing the time spent on the open arms to time spent on the closed arms. AD alone mice
(white box) spent more time in the open arms than AD mice fed J147 (black box) suggesting that J147 treatment reduced the disinhibition
phenotype. (C and D) Fear conditioning to either a cue or a context represents a form of associative learning. The readout that is measured in
contextual and cued fear conditioning is a freezing response that occurs following the pairing of an unconditioned stimulus such as a foot
shock, with a conditioned stimulus such as a particular context or cue (tone). (C) AD mice on the J147 diet (black box) spent much more time
freezing on Day 2, demonstrating a significant improvement in hippocampal related memory compared to AD mice on the control diet (white
box). (D) There was no significant difference in freezing response on day three (cued memory) between AD control and AD mice on J147 diet.
These results suggest that J147 improved the cognitive performance in AD mice. One-way ANOVA and Tukey post hoc test were used to
determine the statistical significance of the behavioral responses, N = 11 AD Control, N = 12 AD + J147. *P <0.05, *** P <0.001.
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during training on Day 1 is then submerged just under
the water level during testing on Day 2 and mice use
spatial cues on the wall around the pool to navigate to
the platform during testing. In Figure 1, visible V4 refers
to visible platform trial 4 (Day 1), which is the last visi-
ble platform trial before testing and, therefore, repre-
sents the baseline. Results from Day 1 indicate no
defects in AD or AD + J147 in the ability to swim or
see as both have similar escape latency. During testing
on Day 2, the time it takes each mouse to find the hid-
den platform during trial 1 (hidden T1) is measured as
escape latency. Results from this two-day water maze
show that AD mice take considerably longer to find the
hidden platform on Day 2 than AD mice treated with
J147 for three months (Figure 1A), demonstrating that
J147 significantly improved the spatial navigational
memory in aged, transgenic AD mice.
There is a growing body of evidence that dementia is
clinically associated with anxiety [34]. The elevated plus
maze measures the anxiety response of mice [13] by
comparing the time spent in the open arm to the time
spent in the closed arm. Anxiety behavior is affected in
transgenic AD mouse models but the results vary con-
siderably according to strain, age and the model used
for the study. AD mice tend to exhibit a disinhibition
phenotype and will spend more time in the open arm
than in the closed arm [35-38]. The level of anxiety in
APPswePS1ΔE9 mice was increased according to one
report [39] whereas in 7-month- and 12-month-old
mice of the same strain, there was a reduction in anxiety
compared to wild type controls [40,41]). A reduction in
anxiety represents a disinhibition phenotype that may be
viewed as akin to that reported in some patients with
Alzheimer’s disease, exemplified by socially unacceptable
behaviors [42]. In addition to the strain and age differ-
ences, variation in the methodology and the laboratory
conditions could interfere with the anxiety and explora-
tion behavior in rodents [43]. These variables could
explain observed differences in results. Our data demon-
strate that aged transgenic AD mice do indeed spend
more time in the open arm, a phenotype that was com-
pletely rescued by treatment with J147 for three months
(Figure 1B).
Fear conditioning measures hippocampal-dependent
associative learning. The read-out measured is a freezing
response where the mouse will freeze if it remembers
and associates that environment with the aversive stimu-
lus. The hippocampus and the amygdala are required for
fear memory [18,19]. Contextual fear conditioning has
previously been carried out with the huAPP/PS1 mice
where 11-month-old AD mice spent significantly less
time freezing in response to the context than wild type
controls [44]. AD mice alone spent significantly less
time freezing in response to the context associated with
the aversive stimulus in our experiment, indicating that
they did not remember the context, a phenotype that
was rescued by treatment with J147 (Figure 1C). There
was no significant difference between the groups on Day
3 of the assay suggesting that the amygdala was not
affected by J147 treatment (Figure 1D).
Results from these behavioral assays show that J147
has the ability to rescue the cognitive decline and disin-
hibition phenotype associated with AD when adminis-
tered at an extremely late stage in the disease
progression when pathology is already far advanced.
J147 reduces soluble levels of Ab
Since it is now believed that soluble Ab polymers are
major contributors to the toxicity associated with the
peptide [45,46] and soluble Ab is the primary contribu-
tor to cognitive dysfunction in line 85 huAPP/PS1 mice
[46], we examined Ab levels in the RIPA insoluble
(100,000 × g pellet) and soluble (RIPA supernatant)
fractions of the hippocampus of J147-treated and con-
trol huAPP/PS1 mice. While Ab1-42 levels as measured
by ELISA were not altered in the RIPA insoluble fraction
in animals fed J147 relative to untreated AD transgenic
animals, Ab1-40 levels were reduced in this fraction
(Figure 2A). Figure 2B, C shows that treatment with J147
decreased the amount of RIPA soluble Ab1-42 and Ab1-40,
respectively, in the hippocampus of aged huAPP/PS1
mice treated with J147 for three months. Thus, J147 has
a small but significant effect on Ab metabolism by redu-
cing both Ab1-40 and Ab1-42 in the soluble fraction of the
hippocampus. Given this effect of J147 on Ab metabo-
lism, we investigated the effect of J147 on the amyloid
precursor protein (APP) processing pathway that leads to
the production of Ab (Figure 2D, E).
The protein level of b-secretase (BACE) in the RIPA
soluble fraction from the hippocampus of J147-treated
mice is significantly reduced compared to the untreated
AD mice (Figure 2D) suggesting that J147 treatment
down-regulated BACE, which is critical for APP clea-
vage that eventually gives rise to Ab [47-51]. This result
is supported by the finding that at the same time that
BACE levels are decreased in the hippocampus, APP
protein levels are significantly increased in the soluble
fractions of hippocampus from the J147-treated AD
mice compared to control AD mice (Figure 2E). Lower
levels of BACE are consistent with a reduction in clea-
vage of the substrate, APP, thereby explaining the
increased levels of APP. Studies indicate that APP is
likely to play a direct role in synaptic structure and
function [52,53].
Since some compounds that reduce memory loss in
AD mice reduce the Ab plaque burden, we next exam-
ined plaque size and density in the hippocampus of
J147-treated and control aged huAPP/PS1 mice. There
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was no difference in either plaque number or size
between control and J147-treated animals (Figure 2F,
G). Therefore, while treatment with J147 enhanced the
cognitive ability of the huAPP/PS1 mice, it had no sig-
nificant effect on plaque load but produced a significant
reduction of soluble Ab levels. This reduction of soluble
Ab levels may be due to the effect of J147 on the APP
processing pathway by down-regulation of BACE.
Neuroprotective pathways targeted by J147
J147 was synthesized and selected for its neurotrophic
ability, in part using assays where it replaced BDNF
Figure 2 J147 reduces soluble levels of Ab. Hippocampal tissue from the aged huAPP/PS1 mice was analyzed for the effect of J147 treatment on
Ab levels. Ab1-40 and Ab1-42 levels were measured by ELISA in control AD animals (black bars) and AD animals fed J147 (grey bars) in the insoluble
(100,000 xg pellet) (A) and RIPA soluble fractions (B and C). J147 treatment decreased insoluble Ab1-40 and both soluble Ab1-40 and Ab1-42 levels. Cell
lysates of hippocampal tissue from the aged huAPP/PS1 and control mice were analyzed for an effect of J147 on the APP processing pathway by
immunoblotting with antibodies against BACE (D) and APP (E). The images were quantified and are represented in the bar graphs accompanying the
Western blot images (D and E). BACE levels were significantly reduced upon treatment with J147 with a corresponding significant increase in APP
levels. Two-tailed P-values ***P <0.001. All data shown are means ± SD, n = 10 to 11 per group. (F) Immunohistochemical analysis was done using
brain coronal sections from these same mice with the antibody 6E10. Sections (30 μ thick) of similar regions from each mouse, (N = 6) were examined
and plaque counts in the hippocampus were quantified. All immunohistochemical images were quantified using Image J Software. (G) The average of
plaque counts for each mouse group is expressed as a number of plaques ± the SD.
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function [7]. J147 increases the levels of BDNF in the
hippocampus of normal rats, as well as in huAPP/PS1
transgenic mice [7], and its synthetic precursor, CNB-
001, increases BDNF levels in rat traumatic brain injury
models [54]. J147 also modulates the expression and/or
phosphorylation of downstream targets of BDNF [7].
Given these previous findings in relation to the BDNF
pathway following J147 treatment, the effect of J147 on
neurotrophic factors was investigated in this AD reversal
study.
Two of the most prominent members of the mamma-
lian neurotrophin family are BDNF and NGF. These
neurotrophic factors stimulate the differentiation,
growth and maintenance of developing neurons in addi-
tion to the survival of mature neurons, and are key
players in synaptic plasticity [55,56], cognition and
memory formation [57-62]. These versatile proteins are
up-regulated in response to neuronal injury and play a
role in the healing process as well as neurogenesis [63,64].
Neurotrophins are synthesized as proneurotrophins,
which may have either neurotrophic or pro-apoptotic
activity [65].
In the AD reversal experiment, J147 treatment
increases both proNGF and mature NGF in the hippo-
campus compared to control huAPP/PS1 mice with the
ratio of proNGF to the mature form being decreased
significantly upon J147 treatment (Figure 3A, B). In
human and rodent brains, proNGF (40 kDa) is the pre-
dominant form. A reduction in the ratio of pro- to
mature NGF with J147 treatment is important given
that proNGF is elevated in AD [66-68], and may contri-
bute to neuronal degeneration [67]. The precursor of
BDNF, proBDNF, is secreted and is processed extracel-
lularly to produce mature BDNF [69-71]. Following
treatment of huAPP/PS1 mice with J147 late in the
course of the disease, there is an increase in both
proBDNF and mature BDNF protein levels in the hippo-
campus, but the ratio of pro- to mature BDNF is
decreased with J147 treatment (Figure 3C, D).
Homer 1, an actin binding protein that is induced by
BDNF [72], belongs to a family of scaffolding proteins
that localize at the postsynaptic density (PSD) [73,74]
and is believed to play a critical role in signal transduc-
tion, synaptogenesis and receptor trafficking at synapses
[75]. Given the increase in BDNF in the hippocampus of
J147-treated mice, we investigated the effect of J147 on
Homer-1 levels. Figure 3E demonstrates that treatment
with J147 significantly increased levels of this protein in
aged AD mice.
Egr3, which belongs to a family of immediate early
genes known as early growth response (Egr) genes, is
another target gene for BDNF. Egr proteins play a role
in the regulation of synaptic plasticity, learning and
memory [76,77] and Egr3 in particular is very important
for the processing of both short term and long term
hippocampal dependent memory [78]. Figure 3F shows
that J147 significantly increased the level of Egr3 in the
hippocampus of J147-treated aged AD mice compared
to control AD mice.
Additional support for an effect of J147 on neurotrophic
pathways came from a study with HT22 cells. HT22 is a
nerve cell line derived from mouse brain and is widely
used to study nerve cell physiology [22,23]. To examine
the effect of J147 on gene expression, a DNA microarray
study probed expression of over 34,000 named mouse
genes. J147 increased transcription factor Egr3 mRNA
expression 8-fold following one hour of treatment, while
Ngf mRNA was up-regulated 2.8-fold (Table 1). HT22
cells do not make BDNF. Also up-regulated was mRNA
from another member of the Egr family, Egr1, with a 2.5-
fold increase and mRNA from a member of the Spred
family, Spred2, with a 2.7-fold increase. J147 did have an
effect on other genes and the Gene Chip data are accessi-
ble through GEO Series accession number GSE45534 [26].
To determine the biological consequences of J147
induction of neurotrophin expression, it was asked if
conditioned media (CM) prepared from HT22 cells trea-
ted with J147 could stimulate neurite outgrowth in
PC12 cells. Both conditioned medium from J147 treated
cells (Figure 3G, middle right panel) and NGF treated
cells promoted neurite outgrowth (Figure 3G, top right
panel), while control medium did not (Figure 3G, top
and middle left panels). This effect was reduced by anti-
NGF anti-sera suggesting that J147 releases neurotro-
phins with an effect on neurites similar to those released
by NGF (Figure 3G, bottom panels). N2 media supple-
ment, which contains transferrin, was added to this
experiment to prevent a non-specific protein-mediated
effect of antibody on neurite outgrowth.
BDNF is a target gene of the cyclic AMP response ele-
ment binding protein (CREB). Following neuronal sti-
mulation the phosphorylation and subsequent activation
of CREB is increased. Furthermore, it is this activity-
dependent increase that is believed to facilitate the tran-
scription of proteins required for learning and memory
[79,80]. CREB phosphorylation is also thought to limit
inflammation [81]. Treatment of aged, transgenic
huAPP/PS1 mice with J147 significantly increased the
amount of phosphorylated CREB in the entorhinal cor-
tex of these mice (Figure 3H) but not in the hippocam-
pus (data not shown). The entorhinal cortex is one of
the first areas to be affected in AD and is the main con-
nection between the hippocampus and neocortex play-
ing an important role in spatial memory [82]. The
entorhinal cortex contains the highest level of choliner-
gic innervations [83] and in AD up to 80% of choliner-
gic axons can be depleted [84]. Conner and colleagues
[85] showed that NGF modulates cholinergic neuronal
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Figure 3 Neuroprotective pathways targeted by J147. Cell lysates of either hippocampal tissue or entorhinal cortex tissue from aged AD
mice on control diet (AD Ctl) or J147 diet (AD J147) were analyzed by Western blotting and the images quantified in bar graphs accompanying
the images. Actin was used as a loading control and all proteins were normalized to actin for quantification purposes. Protein expression levels
of both pro- and mature NGF (A) are up-regulated in the hippocampus of aged huAPP/PS1 mice fed J147 in their diet for three months
compared to control treated mice. (B) The ratio of pro- to mature NGF is decreased in aged huAPP/PS1 mice treated with J147. (C) Levels of
another neurotrophic factor, BDNF, both pro and mature, are also increased in the hippocampus of J147 treated aged huAPP/PS1 mice. (D) The
ratio of pro- to mature BDNF is decreased in aged huAPP/PS1 mice treated with J147. (E) The BDNF responsive protein Homer-1 is also
increased in the hippocampus upon treatment with J147 as did Egr3 (F) another target gene of BDNF. (G) J147 stimulates neurite outgrowth
promoting factor. PC12 cells were plated in growth conditioned medium (CM) prepared from HT22 cells incubated overnight plus or minus 100
nM J147, and as controls fresh DMEM plus 100 nM J147 or fresh DMEM plus 50 ng/ml NGF. Both conditioned medium from J147 treated cells
and NGF promoted neurite outgrowth, while the other conditions did not. This effect was reduced by anti-NGF anti-sera. (H) BDNF is a target
gene of CREB and levels of phosphorylated CREB are significantly increased in the entorhinal cortex by three months of treatment with J147 in
these aged huAPP/PS1 mice. Two tailed P-values, *P <0.05, **P <0.01, and ***P <0.001. All data shown are means ± SD, N = 10 to 11 per group.
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morphology and postulated that NGF acts by strength-
ening the cholinergic projections to the hippocampus
and cortical areas, which consequently may alter neuro-
nal plasticity and lead to improved memory. Therefore,
the effect of J147 on the cholinergic system was investi-
gated using the muscarinic receptor antagonist, scopola-
mine, which decreases central cholinergic neuronal
activity.
J147 and donepezil in a scopolamine induced model of
memory impairment
Cholinergic neurons are among the first to be lost in AD
[86,87] and acetylcholine is the therapeutic target for most
FDA approved drugs for AD [88,89]. Since J147 increases
NGF and NGF is a trophic factor required for cholinergic
neurons, we asked if J147 is effective in an assay depen-
dent upon cholinergic transmission. Scopolamine-induced
memory impairment in rodents is a well established model
of memory dysfunction based upon acetylcholine metabo-
lism [90]. The available data suggest that reversal of scopo-
lamine-induced cognitive impairment is a viable model for
predicting pharmacodynamic signals of cognition enhan-
cing compounds in animals [91]. The acetylcholinesterase
inhibitor, donepezil, which transiently improves cognition
in AD, reverses the cognitive impairment induced by sco-
polamine in both humans and animals [92,93]. We com-
pared J147 to donepezil in the scopolamine-induced
memory impairment model using the same cognitive
behavioral assays that were used for reversal of memory
impairment in old AD mice. Mice were given J147 alone,
donepezil alone and J147+donepezil in food before the
cognitive behavioral assays, including the Y-maze, a two-
day water maze and fear conditioning were done in the
presence of scopolamine treatment. These assays have pre-
viously been used to probe deficits with scopolamine treat-
ment [94-97].
In all of the assays, mice received an i.p. injection of
scopolamine (1 mg/kg) 30 minutes before testing, while
one of the groups on the control diet received an i.p.
injection of saline. Mice were tested in the Y maze cogni-
tive behavioral assay first. The spontaneous tendency to
alternate free choices in entering the three arms of the Y
maze is a measure of short-term working memory
[20,21]. Scopolamine-treated mice made a lower percen-
tage of spontaneous alternations (defined as consecutive
entries into the three different arms) in this test
compared to saline controls and all three treatment
groups returned this phenotype almost to control levels
(Figure 4A). These data indicate that J147, donepezil and
J147+donepezil all improve short-term working memory.
Next, mice were observed in the two-day water maze
behavioral assay which involves training mice on Day 1
with a visible platform and visual cues and hiding the
platform on Day 2. The scopolamine-treated mice took
a considerable amount of time to find the hidden plat-
form compared to saline controls (Figure 4B). Both J147
and the combination of J147+donepezil rescued this def-
icit in spatial memory created by scopolamine to a simi-
lar extent, but donepezil alone failed to rescue the
deficit (Figure 4B).
Lastly, mice were tested in the fear conditioning beha-
vioral assay. Mice were trained on Day 1 to associate their
environment with an aversive stimulus (a foot shock). The
amount of time spent freezing in response to the environ-
ment is measured on Day 2 as hippocampal dependent
memory, whereas the amount of time spent freezing in
response to the tone on Day 3 is related to hippocampus
and amygdala function. The scopolamine-treated mice
spent significantly less time freezing than saline controls
in response to the context indicating they did not remem-
ber the environmental context (Figure 4C). While J147
treatment did appear to slightly improve contextual
memory compared to scopolamine, it was not significant
(Figure 4C). Donepezil did not improve memory with the
mice showing freezing times similar to scopolamine
(Figure 4C). However, the combination of J147+donepezil
significantly improved memory compared to scopolamine
suggesting a synergistic effect of the two compounds in
this assay of hippocampal-dependent associative memory
(Figure 4C). Scopolamine-treated mice also spent signifi-
cantly less time freezing in response to the tone compared
to saline controls (Figure 4D). J147 treatment as well as
donepezil treatment appeared to rescue the phenotype
although neither effect was significant (Figure 4D).
Table 1 Top up-regulated genes one-hour treatment J147
Gene symbol Gene title Entrez gene Fold change:
J147 (1 hr) vs Control
Egr3 early growth response 3 13655 8.0
Ngf nerve growth factor 18049 2.8
Spred2 sprouty related, EVH1 domain containing 2 114716 2.7
No title (chr8:13161324 to 13161817) 2.6
Egr1 early growth response 1 13653 2.5
DNA microarray was used to evaluate changes in gene expression following one hour of treatment of HT22 neuronal cells with 10 μM J147. The top five genes
showing increases in mRNA expression are shown in this table with Egr3 and NGF being the top two of over 34,000 named mouse genes probed.
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However, the combination of J147 and donepezil signifi-
cantly reversed the memory deficit caused by scopolamine
treatment (Figure 4D).
Pharmacology, safety and target screening of J147
The pharmacokinetics of J147 in the mouse brain and
plasma were evaluated using standard procedures. Blood
and brain distribution of J147 following per oral (PO)
administration was plotted for mice as a function of
time (Figure 5). The half life of J147 was calculated at
1.5 hrs in plasma and 2.5 hrs in brain (Figure 5B and
5C, respectively). The bioavailability of J147 following
oral administration was calculated at 28%. The safety of
J147 was evaluated using acute toxicity, the hERG assay,
CYP450 3A4 assays and the Ames test, all of which
were negative. Rats and mice received 2 g/kg of J147 to
probe acute toxicity, yielding negative results (done by
Absorption Systems (San Diego, CA, USA). In contrast,
the oral LD50 in mice of the widely prescribed donepezil
is 45 mg/kg (Pfizer, MSDS, Pfizer Inc, NY, NY, USA). A
CeeTox assay also demonstrated “Safe” up to 90 mM
J147 plasma concentration (done by CEETOX, Inc., Kala-
mazoo, MI, USA), and when J147 was fed at 10 mg/kg/day
throughout pregnancy to mice, offspring were normal.
MDRI-MDCK brain transport rates classified J147 as
“High” (done by Absorption Systems), and there was mod-
erate and symmetrical penetration in the Caco-2 assay
(Absorption Systems). Additional de-risking and target
identification screens were carried out at 10 μM J147 by
various CROs (Table 2). No significant reproducible inhi-
bition above 60% was observed except for monoamine oxi-
dase B (MAO B) and the dopamine transporter. Dose
Figure 4 J147 and donepezil in a scopolamine induced model of memory impairment. C57BL6/J male mice aged eight weeks were
assigned to five groups, 12 mice per group, and treated with compounds in their food for two weeks. Groups included J147 (200 ppm),
donepezil (20 ppm), combination of J147 and donepezil (200 ppm and 20 ppm, respectively) and two control groups. Memory impairment was
induced with scopolamine at 1 mg/kg 30 minutes before behavior testing in all groups except one of the control groups, which received saline
as a control. Mice were analyzed for working memory by the Y-maze, for spatial memory by the two-day water maze, and hippocampal
dependent memory by fear conditioning. (A) Scopolamine significantly decreased the percent of spontaneous alternations made by mice
compared to saline-injected control. Treatment with J147 and donepezil alone, as well as the drugs together, prevented this decrease. (B)
Treatment with scopolamine significantly increased the time taken to find the platform compared to saline controls in the two day water maze.
J147 prevented the loss in spatial working memory, whereas donepezil did not. (C) On Day 2 of the fear conditioning assay the amount of time
freezing in response to the environment is measured as contextual memory. Scopolamine significantly decreased the freezing response and
while J147 did increase the freezing response compared to scopolamine it was not significant. However the J147 and donepezil together did
appear to have a synergistic effect. (D) On Day 3 the amount of time freezing in response to the tone is measured as emotional memory.
Scopolamine significantly decreased the freezing response. While J147 and donepezil alone did increase the freezing response compared to
scopolamine, it was not significant. However, J147 and donepezil together had a synergistic effect with the combination significantly increasing
the freezing response compared to scopolamine control. One-way ANOVA with Tukey post hoc test, P-value, *P <0.05, **P <0.01, and ***P <0.001.
All data shown are means ± SD, N = 7 to 8 per group.
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response curves were done for each, yielding EC50s of 1.88
μM and 0.649 μM, respectively. The EC50 of J147 is less
than 100 nM in neuroprotection assays [7]. Inhibition of
the dopamine transporter can lead to addiction, but no
addiction to J147 was observed in mice (study conducted
by Dr. Amanda Roberts, Scripps Research Institute). All
original data are available upon request.
Discussion
The broad neuroprotective activity of the potent, orally
active compound J147 was initially described in a double
transgenic AD mouse model (APP/swePS1ΔE9). In this
model, J147 maintained learning and memory, as well as
synaptic proteins, and reduced biochemical markers of
inflammation and soluble Ab levels [7]. Over 200 com-
pounds appear to alter Ab metabolism or behavioral
deficits in AD transgenic mice [30] but none have trans-
lated into AD therapeutics [98]. The reason for the lack
of translation may be that many of these compounds
are only effective when administered before pathology is
present; yet, in humans, pathology is usually quite
advanced at diagnosis and treatment.
To test the efficacy of J147 in a much more rigorous
preclinical AD model, we treated mice using a therapeu-
tic strategy more accurately reflecting the human symp-
tomatic stage. Another mouse preclinical screening trial
targeted the symptomatic stage (between 9 and 11
months) [44] and a study with a plant extract [99] used
23- to 24-month-old mice, but to our knowledge no che-
mically defined AD drug candidate has been tried at the
more pathologically advanced stage used in this study.
Our strategy involved a 3-month J147 treatment in
huAPP/PS1 transgenic AD mice aged to 20 months, an
age in which severe behavioral deficits and AD pathology
manifest [10]. The goal was to investigate the ability of
J147 to rescue cognitive impairment at a late stage in the
disease as an indicator of its potential to rescue cognitive
impairment in humans with AD. We report here a rever-
sal of cognitive impairment in aged huAPP/PS1 mice by
J147 and provide evidence that these beneficial effects are
due to the ability of J147 to normalize several different
aspects of AD pathology, likely through the up-regulation
of the neurotrophin pathway.
Tests that assess distinct aspects of memory can be
performed in rodents. Spatial memory is assessed using
Figure 5 Pharmacokinetic profile of J147 in mice. (A) The pharmacokinetic profile of J147 in mice was done by Pharmaron (Louisville, KY,
USA). Plasma (B) and brain (C) distribution of J147 was plotted as a function of time following or per oral (PO) administration at 20 mg/kg.
Table 2 Screening for target and off target effects
Screen Company
Lead Profile Screen (60 CNS receptors/transporters) Ricerca-MDS
Protein Kinase Screen (50 kinases - activity) Nova Screen
Protein Kinase (352 kinases - binding) Ambit
All phosphatases (Tyr and Ser/Thr) Caliper
Known proteases Caliper and
Ricerca
Deubiquitinases, Esterases, Secretases, Caspases Caliper
5-, 12-, 15-LOX, COX-1 and 2, NADPH oxidase MDS
Deacetylase, Sirtuin SIRT-1, -2, -3, Proteasome, MAO A
and B
Ricerca
All phosphodiesterases and 5-CYPs MDS
Various CROs screened a wide variety of potential targets at 10 μM J147 with
no significant reproducible inhibition above 60% except for monoamine
oxidase B (MAO B) and the dopamine transporter.
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the Morris Water Maze [100] and hippocampal-depen-
dent associated memory is analyzed by using a fear con-
ditioning assay [101]. In addition, the anxiety response
of rodents can be measured using the elevated plus
maze, an assay in which AD mice show a disinhibition
phenotype [37,38]. In the AD reversal treatment strategy
described here, J147 significantly improved several dif-
ferent aspects of memory affected in AD, including spa-
tial memory, a disinhibition phenotype and hippocampal
dependent associative learning (Figure 1).
J147 treatment also resulted in a significant effect on
Ab metabolism, reducing levels of soluble Ab without
an effect on plaque density or size (Figure 2). This find-
ing is important considering the accumulating evidence
that soluble Ab directly causes cognitive dysfunction
[102,103] and the fact that improved cognition in 3xTg
AD mice can manifest without a reduction in Ab plaque
load [104]. Our data (Figures 1 and Figure 2) support
this hypothesis. In addition, Zhang and colleagues
observed that soluble Ab is responsible for learning and
memory deficits in the huAPP/PS1 mice used in these
studies [46]. Our data suggest that the reduction in
soluble Ab levels in the hippocampus of treated, aged
AD mice compared to control AD mice by J147 is due
to an effect on the APP processing pathway as J147
decreased the protein level of the BACE enzyme leading
to an increase in APP levels (Figure 2D, E).
J147 treatment of aged huAPP/PS1 mice increases the
expression levels of several proteins involved in neurotro-
phin signaling. Members of the neurotrophin family
maintain neuronal survival, axonal guidance and cell mor-
phology and are key players in cognition and memory for-
mation [55,56]. Neurotrophic factors are perturbed in AD
and unevenly distributed due to impairment in axonal
transport [105]. It is this imbalance in the AD brain that
leads to the observed increase in proNGF in the hippo-
campus where it is synthesized [106,107] and its reduction
in the basal forebrain [108,109]. NGF maintains and regu-
lates the cholinergic phenotype of basal forebrain neurons
[110,111]. Figure 3B shows that J147 decreases the ratio of
pro- to mature NGF in the hippocampus, which is impor-
tant given that proNGF is elevated in AD brain [66-68]
and may lead to neuronal degeneration [67]. J147 may act
to restore the balance between pro- and mature NGF
which could allow transport of NGF to the basal forebrain
neurons. Results from in vitro experiments with the neu-
ronal HT22 cells also suggest an effect of J147 on NGF
synthesis and secretion. J147 treatment of HT22 cells for
one hour increased NGF mRNA by 2.8-fold in a DNA
microarray experiment (Table 1) and conditioned medium
from J147 treated HT22 cells stimulated neurite growth in
PC12 cells in a NGF-dependent manner (Figure 3G).
BDNF, a target gene of CREB, is reduced with age and in
the AD brain [112] and is required for normal cognitive
function [113]. We previously demonstrated that J147 up-
regulates the BDNF pathway in huAPP/PS1 mice follow-
ing seven months of treatment, and here we show that
even when administered at a stage when pathology is
advanced, J147 can significantly increase two factors criti-
cal for memory formation: CREB phosphorylation and
BDNF expression (Figure 3H and 3C, respectively). An
increase in both pro- and mature BDNF suggests an
increase in BDNF synthesis and secretion from neurons
while the decrease in the ratio of pro- to mature BDNF
(Figure 3D) suggests higher levels of secreted BDNF.
Further evidence for the up-regulation of BDNF signaling
comes from the finding of increased levels of Homer-1
and Egr-3 (Figure 3E, F), which are genes activated by
BDNF. Thus the phosphorylation of CREB by J147 could
increase the levels of BDNF, which consequently may
increase BDNF responsive proteins. Hippocampal levels of
both BDNF and NGF have been correlated with cognitive
performance in animal models [114,115] and administra-
tion of these neurotrophic factors reduces memory loss in
aging or animal models of AD [116,117], further substan-
tiating their importance for memory. The effect of J147 on
both NGF and BDNF levels reported here, as well as its
effect on BDNF target genes, may explain the memory def-
icit reduction observed in the aged huAPP/PS1mice trea-
ted with J147 (Figure 1).
Neurotrophic factors have been pursued as appealing
candidates for the treatment of neurodegenerative dis-
eases, neuropathies and peripheral nerve injury [118,119].
However, delivering growth factors to the brain has
proved difficult and risky for patients with significant
side effects observed [120], such as sprouting of sensory
and sympathetic neurons [121], and neuropathic pain
[120]. Treatment strategies involving neurotrophic fac-
tors are now based on the transfer of genes, molecules or
cells into the nervous system [122]. NGF is in fact viewed
as a viable target for AD clinical trials with one group
investigating NGF ex vivo gene delivery in a Phase 1 trial
with human patients aimed at stimulating cholinergic
function and improving memory [123]. This small study
found improvement in the rate of cognitive decline but
the procedure requires delivery directly into the brain.
Perhaps, a molecule that could stimulate neurotrophic
factors, such as NGF in vivo, would be more efficient,
more safe and cost effective than gene delivery directly
into the brain.
Scopolamine is a well known competitive muscarinic
receptor antagonist that causes reproducible, transient
impairments across multiple cognitive domains in
healthy animals and non-diseased humans by decreasing
central cholinergic neuronal activity [124,125]. The abil-
ity of compounds to reverse scopolamine-induced cogni-
tive impairment is used as a model for demonstrating
drug target engagement and cognitive enhancement in
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both humans and animals [91]. In this study, we utilized
the scopolamine model to compare J147 to donepezil,
the currently most widely used AD drug. Three different
behavioral assays, Y-maze, two-day water maze and fear
conditioning, which have previously been used to assay
deficits with scopolamine treatment [94-97] compared the
ability of compounds to reverse cognitive impairment
induced by scopolamine. All three assays demonstrated
cognitive deficits with scopolamine treatment compared
to saline controls (Figure 4A-D). Results from the treat-
ment groups revealed that all three groups, J147, donepezil
and J147+donepezil, rescued the decrease in spontaneous
alternations induced by scopolamine demonstrating an
improvement in short-term working memory (Figure 4A).
J147 and J147 + donepezil rescued the deficit in spatial
navigational memory caused by scopolamine in the water
maze but donepezil alone failed to rescue the deficit
(Figure 4B). In the fear conditioning paradigm, only the
combination of J147 and donepezil rescued the hippocam-
pal-dependent deficit in contextual and cued fear condi-
tioning, suggesting the compounds’ synergistic effect for
this particular type of memory (Figure 4C, D). Demonstra-
tion of synergism between the two compounds may be
important for clinical trials as the majority of patients
recruited to a trial will likely already be on donepezil
treatment.
The pharmacokinetic properties of J147 after a single
dose of 20 mg/kg in mice show brain levels of about
600 nM at 2 h, over 10-fold above its EC50 in some cell
culture neuroprotection assays [7], with a brain to blood
ratio of approximately 0.5. The bioavailability of J147
following PO administration in mice was calculated at
28%. Positive data for blood brain barrier (BBB) penetra-
tion (High) were also obtained for J147 using the
MDCK-MDRI cell culture model for assaying the BBB
penetration potential of drugs. Acute toxicity studies
showed no oral toxicity of J147 in mice at the maximum
testable dose of 2 gm/kg and other safety tests including
hERG, CYP450 inhibition and Ames were also negative
which further supports the safety of J147. In the search
for the target of J147, many potential off target effects
have been ruled out (Table 2), once again suggesting the
safety of J147. The data collected to date suggest that
J147 has good pharmacokinetic and safety profiles.
Conclusions
In conclusion, the range of biological activities of J147
relevant to human AD is quite extensive. When admi-
nistered in food at a stage when pathology is advanced
in 20-month-old transgenic AD mice, J147 rescued the
severe loss of cognitive function, reduced soluble levels
of Ab and increased neurotrophic factors essential for
memory. When compared to donepezil in memory
assays, J147 performed equally well or superior, and
even showed synergistic effects in the fear conditioning
assay. In addition, J147 has good medicinal chemical
and pharmacological properties for a CNS drug, has few
off-target effects and is orally active [7]. Thus, J147 is an
exciting, new compound with strong potential to be an
AD therapeutic by slowing disease progression through
neuroprotection as well as providing rapid cognition
benefits by reversing cognition deficits following short-
term treatment. These dual attributes improve the
chances for success in clinical trials as a disease-modify-
ing drug, and seems ideally suited for rapid progress
through the new FDA guidelines for AD trials [126].
We hypothesize that the mechanism of action of J147 is
related to its ability to increase the levels of BDNF and
NGF, and studies are being conducted to identify its
molecular target.
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